Eyenovia

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Eyenovia anticipates FDA approval for MydCombi, focusing on growth

Eyenovia's Q4 2022 call highlighted financial results, key milestones, and upcoming FDA approval for MydCombi. The company's focus on product candidates and strategic partnerships positions it for growth.

Eyenovia reports FDA approval for MydCombi, eyes ophthalmology market growth

Eyenovia's Q1 2023 performance reflects financial discipline and strategic progress in product development and partnerships, positioning the company for future growth.
The company's focus on efficiency, market potential in ophthalmology, and innovative products like Optejet present opportunities for expansion and value creation.
Challenges lie in raising awareness about new products, balancing financial discipline with growth ambitions, and successfully executing product launches in competitive markets.

Eyenovia reports Q2 loss but hits milestones, eyes growth opportunities

Eyenovia's Q2 2023 performance reflects a net loss but highlights successful commercial milestones for Mydcombi and progress on Apersure.
The company's strengths lie in innovation with Optejet technology, expanding manufacturing capabilities, and promising licensing agreements.
Challenges include managing losses, finalizing partnerships, and meeting regulatory timelines, while opportunities exist in partnerships, market expansion, and revenue growth.
Overall, Eyenovia's strategic focus on product development, partnerships, and financial management positions it for future growth and success in the pharmaceutical industry.

Eyenovia reports Q3 losses, eyes FDA approvals and strategic partnerships

Eyenovia's Q3 performance reflects strategic investments in product development and partnerships to drive future growth. The company's focus on innovative products like Mydcombi and APP13007 positions them well for market expansion. While facing financial challenges and regulatory risks, Eyenovia's strong leadership and partnership progress indicate a promising outlook for the future.

Eyenovia reports Q4 progress with FDA approvals and revenue strategies

Eyenovia's Q4 2023 earnings call highlighted progress in product development, manufacturing capabilities, and revenue potential.
The company's focus on innovation, competitive pricing, and strategic partnerships positions it for future growth and market success.
Challenges include market competition, operational expenses, and the need for promotional efforts to drive product adoption.
Opportunities lie in collaborations, product launches, and strategic initiatives to enhance market presence and drive revenue growth.

Eyenovia reports Q1 loss but eyes revenue growth opportunities

Eyenovia's Q1 2024 performance reflects a focus on commercialization, pipeline advancement, and strategic collaborations amidst a net loss and increased expenses.
With a strong product portfolio, differentiated offerings, and key partnerships, Eyenovia is well-positioned to capitalize on revenue opportunities in the eye care market.
While facing challenges in managing costs and securing capital, Eyenovia has opportunities to drive growth through product launches, market expansion, and regulatory milestones.

Eyenovia reports Q2 loss but sees growth potential in innovations

Eyenovia's Q2 2024 performance reflects strategic investments in product development and partnerships, with a focus on innovative technologies like Optejet.
While facing financial challenges from increased expenses, Eyenovia's revenue potential from licensing agreements and product pipeline remains strong.
The company's opportunities lie in capitalizing on Optejet advancements, expanding market reach through collaborations, and navigating regulatory milestones for key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Eyenovia (EYEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now

The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041 The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8,695,653 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,695,653 shares of common stock in a registered direct offering at a combined offering price of $0.46 per share and accompanying warrant. The warrants have an exercise price of $0.50 per share, will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about September 30, 2024, subject to the satisfaction of customary closing conditions.

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol's prescribing information New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol's prescribing information

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

TAIPEI , Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora Pharmaceuticals Ophthalmic (hereinafter referred to as "Bora," 6472.TW).

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024 Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering").

Eyenovia Announces Closing of Public Offering

Eyenovia Inc EYEN stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro.

Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering").

Eyenovia Announces Pricing of $5.14 Million Public Offering

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof) in a best efforts offering. All of the securities to be sold in the offering are to be offered by Eyenovia. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering (the "Offering").

Eyenovia, Inc. Announces Proposed Public Offering

Eyenovia (EYEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know

Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer Bren Kern - Chief Operating Officer John Gandolfo - Chief Financial Officer Conference Call Participants Matt Kaplan - Ladenburg Kemp Dolliver - Brookline Capital Markets Lachlan Hanbury-Brown - William Blair Matthew Caufield - H.C. Wainwright Operator Greetings.

Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript

Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.16 per share a year ago.

Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates

Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

Product-candidate would incorporate new steroid with the Optejet® for the millions of dry eye patients who experience periodic flare-ups Product-candidate would incorporate new steroid with the Optejet® for the millions of dry eye patients who experience periodic flare-ups

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

TAIPEI , Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovia", NASDAQ: EYEN), whereby the companies will co-develop Clobetasol Propionate Ophthalmic Suspension 0.05% ("clobetasol propionate") for the short-term relief of dry eye disease.  Both companies will conduct due diligence and work toward a definitive agreement that will include the sharing of development costs and the division of profit upon commercialization.

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sources

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

Collaboration to focus on the development of a formulation of Senju's SJP-0035 for use with Eyenovia's Optejet® dispensing technology, following consultation with FDA

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

NovaBay Pharmaceuticals

EMERYVILLE, Calif. & NEW YORK--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, have commenced activities under a previously announced co-promotion agreement. Under the agreement, Eyenovia is leveraging its ten-person field salesforce to promote.

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder, providing for the purchase and sale of 7,575,757 shares of common stock, and warrants to purchase up to 7,575,757 shares of common stock (the "Offering"). The combined offering price for each share of common stock and accompanying warrant is $0.66.

Eyenovia Announces Pricing of $5M Registered Direct Offering

Aqua Metals

EVgo

Immunic Inc

Profire Energy

Village Farms International

Penny stocks with insider buying addresses a key lingering concern among speculators: do the folks that are selling me their business actually believe in their business? I'm telling you, there's nothing worse than putting your money down into an opportunity, only to discover that the very people who are selling you on the idea – indeed, the insiders that know the business the best – are the ones exiting the enterprise.

News for Eyenovia Stock (EYEN)